Search

Displaying results 1441 - 1450 of 5392 in total
  1. Drug

    Scutellaria baicalensis root

    go.drugbank.com/drugs/DB14364
    Investigational

    Scutellaria baicalensis root is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  2. Drug

    Typhonium giganteum whole

    go.drugbank.com/drugs/DB14369
    Investigational

    Typhonium giganteum whole is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  3. Drug

    Phellodendron amurense bark

    go.drugbank.com/drugs/DB14370
    Investigational

    Phellodendron amurense bark is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  4. Drug

    Glutathione

    go.drugbank.com/drugs/DB00143
    ApprovedInvestigationalNutraceutical

    A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.

    Mixtures: Oil
  5. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a ...

  6. Drug

    Ruplizumab

    go.drugbank.com/drugs/DB06475
    Investigational

    Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.

  7. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.

  8. Drug

    Tirbanibulin

    go.drugbank.com/drugs/DB06137
    ApprovedInvestigational

    [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.

  9. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.

  10. Drug

    Oxitriptan

    go.drugbank.com/drugs/DB02959
    ApprovedInvestigationalNutraceuticalWithdrawn

    5-Hydroxytryptophan (5-HTP), also known as oxitriptan (INN), is a naturally occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in